3SBio Inc (83B) - Total Assets
Based on the latest financial reports, 3SBio Inc (83B) holds total assets worth €36.25 Billion EUR (≈ $42.38 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of 3SBio Inc to assess how comfortably operating cash covers total debt obligations.
3SBio Inc - Total Assets Trend (2016–2025)
This chart illustrates how 3SBio Inc's total assets have evolved over time, based on quarterly financial data. See 83B total equity for net asset value and shareholders' equity analysis.
3SBio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
3SBio Inc's total assets of €36.25 Billion consist of 62.5% current assets and 37.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.8% |
| Accounts Receivable | €1.01 Billion | 2.8% |
| Inventory | €1.05 Billion | 2.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.76 Billion | 4.9% |
| Goodwill | €4.17 Billion | 11.5% |
Asset Composition Trend (2016–2025)
This chart illustrates how 3SBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 3SBio Inc (83B) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 3SBio Inc's current assets represent 62.5% of total assets in 2025, an increase from 20.3% in 2016.
- Cash Position: Cash and equivalents constituted 42.8% of total assets in 2025, up from 6.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, a decrease from 57.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 11.5% of total assets.
3SBio Inc Competitors by Total Assets
Key competitors of 3SBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
China | CN¥3.22 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥3.65 Billion |
3SBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.13 | 1.71 | 4.60 |
| Quick Ratio | 4.90 | 1.57 | 4.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €18.26 Billion | €3.88 Billion | €5.23 Billion |
3SBio Inc - Advanced Valuation Insights
This section examines the relationship between 3SBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.75 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 49.7% |
| Total Assets | €36.25 Billion |
| Market Capitalization | $5.59 Billion USD |
Valuation Analysis
Below Book Valuation: The market values 3SBio Inc's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: 3SBio Inc's assets grew by 49.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 3SBio Inc (2016–2025)
The table below shows the annual total assets of 3SBio Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €36.25 Billion ≈ $42.38 Billion |
+49.72% |
| 2024-12-31 | €24.21 Billion ≈ $28.31 Billion |
+2.49% |
| 2023-12-31 | €23.63 Billion ≈ $27.62 Billion |
+7.44% |
| 2022-12-31 | €21.99 Billion ≈ $25.71 Billion |
+14.45% |
| 2021-12-31 | €19.21 Billion ≈ $22.46 Billion |
+8.68% |
| 2020-12-31 | €17.68 Billion ≈ $20.67 Billion |
+19.37% |
| 2019-12-31 | €14.81 Billion ≈ $17.31 Billion |
+7.01% |
| 2018-12-31 | €13.84 Billion ≈ $16.18 Billion |
+0.63% |
| 2017-12-31 | €13.75 Billion ≈ $16.08 Billion |
+24.59% |
| 2016-12-31 | €11.04 Billion ≈ $12.91 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more